ReviewInternational journal of molecular sciences2024
Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options.
Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 64 citations in OpenAlex.
- From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases.Annals of medicine · 2026Review
- Post-Exposure JNJ-26366821 Treatment Attenuates Systemic Inflammation and Limits Cardiotoxic Risk.Biomolecules · 2026Article
- Review
- Design of a modified platelet immunofluorescence test to assess platelet-reactive antibody burden and its association with platelet functional exhaustion and clinical features in chronic immune thrombocytopenia.British journal of haematology · 2026Article
- Severe intraoperative bleeding as the initial manifestation of de novo immune thrombocytopenia during lumbar spinal fusion: a case report.European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026Article
- Is Total Hip Arthroplasty Feasible in Patients with Severe Preoperative Thrombocytopenia Managed by a Structured Perioperative Protocol? A Propensity Score-Matched Cohort Study.Journal of clinical medicine · 2026Article
- Article
- Association and exploratory clinical significance of peripheral blood mononuclear cell microRNA-155 with T-Cell subset imbalance in newly diagnosed paediatric immune thrombocytopenia.BMC pediatrics · 2026Article
- Prediction of avatrombopag-induced thrombocytosis in pediatric immune thrombocytopenia: an AI-based real-world study.Annals of hematology · 2026Article
- Biosynthetic and genetic pathways related to sialic acid metabolism.The Journal of biological chemistry · 2026Review
- Thrombocytopenia in Pregnancy: Clinical Challenges, Maternal-Fetal Risks, and Management Strategies.Life (Basel, Switzerland) · 2026Review
- Proteomic Analysis in Search of New Biomarkers of Immune Thrombocytopenia (ITP)-A Review of Current Data.Proteomes · 2026Review
- Glycoside Compounds from Blood-Nourishing Chinese Medicinal Herbs: Structural Characteristics, Pharmacological Mechanisms, and Therapeutic Potential for Thrombocytopenia.Molecules (Basel, Switzerland) · 2026Review
- Differences in functional cross-talk between loops C and D in two mitochondrial cytochromes.Journal of inorganic biochemistry · 2026Article
- Successful Treatment With Rituximab for Severe Immune Thrombocytopenic Purpura During Hemodialysis.Cureus · 2026Article
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- Clinical Characteristics and Predictors of Chronicity in Children With Immune Thrombocytopenia.Cureus · 2026Article
- Life-threatening intraparenchymal hematoma due to immune thrombocytopenic purpura: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- A Clinician Perspective for a Personalized Approach to Management of Chronic Immune Thrombocytopenia with Targeted Therapies Alone or in Combination.Journal of clinical medicine · 2026Review
- Ningxue Shengban decoction containing serum alleviates immune thrombocytopenia by modulating CD4Stem cell research & therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of immune thrombocytopenia (ITP) and the prediction of patient response to therapy still represent a significant and constant challenge in hematology. ITP is a heterogeneous disease with an unpredictable evolution. Although the pathogenesis of ITP is currently better known and its etiology has been extensively studied, up to 75% of adult patients with ITP may develop chronicity, which represents a significant burden on patients' quality of life. A major risk of ITP is bleeding, but knowledge on the exact relationship between the degree of thrombocytopenia and bleeding symptoms, especially at a lower platelet count, is lacking. The actual management of ITP is based on immune suppression (corticosteroids and intravenous immunoglobulins), or the use of thrombopoietin receptor agonists (TPO-RAs), rituximab, or spleen tyrosine kinase (Syk) inhibitors. A better understanding of the underlying pathology has facilitated the development of a number of new targeted therapies (Bruton's tyrosine kinase inhibitors, neonatal Fc receptors, strategies targeting B and plasma cells, strategies targeting T cells, complement inhibitors, and newer TPO-RAs for improving megakaryopoiesis), which seem to be highly effective and well tolerated and result in a significant improvement in patients' quality of life. The disadvantage is that there is a lack of knowledge of the predictive factors of response to treatments, which would help in the development of an optimized treatment algorithm for selected patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.